Balance Sheet Insights: Novo Nordisk ADR (NVO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Novo Nordisk ADR (NYSE: NVO) closed at $123.70 down -2.99% from its previous closing price of $127.51. In other words, the price has decreased by -$2.99 from its previous closing price. On the day, 6.77 million shares were traded. NVO stock price reached its highest trading level at $125.2732 during the session, while it also had its lowest trading level at $122.9415.

Ratios:

For a deeper understanding of Novo Nordisk ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 45.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 35.10. For the most recent quarter (mrq), Quick Ratio is recorded 0.75 and its Current Ratio is at 0.94. In the meantime, Its Debt-to-Equity ratio is 0.51 whereas as Long-Term Debt/Eq ratio is at 0.46.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on May 30, 2024, initiated with a Buy rating and assigned the stock a target price of $156.

On April 12, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $163.

On January 23, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $120.Morgan Stanley initiated its Overweight rating on January 23, 2024, with a $120 target price.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 554350411776 and an Enterprise Value of 545823490048. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 42.46, and their Forward P/E ratio for the next fiscal year is 28.93. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 15.16. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.04 while its Price-to-Book (P/B) ratio in mrq is 33.76. Its current Enterprise Value per Revenue stands at 2.116 whereas that against EBITDA is 4.313.

Stock Price History:

Over the past 52 weeks, NVO has reached a high of $148.15, while it has fallen to a 52-week low of $86.96. The 50-Day Moving Average of the stock is -7.12%, while the 200-Day Moving Average is calculated to be -1.83%.

Shares Statistics:

For the past three months, NVO has traded an average of 3.86M shares per day and 3827500 over the past ten days. A total of 3.38B shares are outstanding, with a floating share count of 3.34B. Insiders hold about 0.02% of the company’s shares, while institutions hold 10.07% stake in the company. Shares short for NVO as of 1724976000 were 5126269 with a Short Ratio of 1.33, compared to 1722384000 on 4050090. Therefore, it implies a Short% of Shares Outstanding of 5126269 and a Short% of Float of 0.16.

Dividends & Splits

According to the company, the forward annual dividend rate for NVO is 1.45, from 9.9 in the trailing year. Against a Trailing Annual Dividend Yield of 0.077640966The stock’s 5-year Average Dividend Yield is 1.5.

Most Popular